Introduction
============

Although advances in the oncological treatment of metastatic renal cell carcinoma (mRCC) have been made, the prognosis is still poor. Finding molecular targets for RCC has been an area for research in recent years. This work has led to the establishment of new therapeutic agents: the tyrosine kinase inhibitors (TKI) sunitinib, sorafenib, pazopanib and axitinib [@B1]. Sunitinib, which is the focus for the current study, targets the receptors of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) [@B2]. For sunitinib given as first line treatment in metastatic disease, the median progression free survival (PFS) extends to 11 months in selected patients [@B3].

Defining predictive factors is key to select the individuals that will benefit from medication. At the same time, patients without benefit from for example TKI treatment, can avoid possible severe and sometimes even chronic toxicity. In addition, by establishing a predictive marker, the cancer treatment costs can be reduced.

There is currently no predictive marker for RCC treatment but some candidates have been proposed. The majority of the studies have investigated the potential of serum proteins to predict the response to sunitinib therapy [@B4], [@B5], [@B6]. Development of hypertension which is a common side effect of sunitinib treatment is associated with a significantly longer PFS and overall survival (OS) in patients with mRCC [@B7].

Annexins belong to a well-known multigene family of Ca^2+^-regulated phospholipid-binding and membrane-binding proteins [@B8]. They are characterized by the unique architecture of their Ca^2+^-binding sites, which enables them to peripherally dock onto negatively charged membrane surfaces in their Ca^2+^-bound conformation [@B9]. Annexins are involved in cellular processes, including apoptosis, proliferation and differentiation [@B8], [@B9]. In vertebrates, 12 annexin subfamilies (A1-A11 and A13) have been identified [@B10]. Annexin 1 (ANXA1) has potential anti-inflammatory activity since it inhibits phospholipase A2, potent mediators of inflammation, prostaglandins and leukotrienes [@B11]. In addition, ANXA1 may stimulate VEGF-mediated angiogenesis [@B12].

Among the annexin A group, A1, A2, A4 and A5 play important roles in breast cancer, pancreatic cancer and laryngeal carcinoma by regulating apoptosis, carcinogenesis, migration and invasion of cancer cells [@B13]. ANXA1 is differentially expressed in tumor cells with variable expression ranging from high levels to lack of ANXA1 expression ([www.proteinatlas.org](http://www.proteinatlas.org)) [@B14], [@B15]. A low ANXA1 expression is observed in oesophageal squamous cell carcinoma whereas a high expression is found in colorectal cancer [@B16]. In another previous study, ANXA1 expression was significantly upregulated in gastric adenocarcinoma cells and was closely related to the depth of tumor invasion, lymph node metastasis, distant metastasis and TNM stage. A high ANXA1 expression was associated with a poor prognosis in these patients [@B16]. In another study, ANXA1 was highly expressed in cholangiocarcinoma but to a low extent in hepatocellular carcinoma [@B17]. In patients with invasive breast cancer, tumoral overexpression of ANXA1 was related to unfavorable prognostic factors [@B18].

ANXA1 is ubiquitously expressed in normal human tissues, with high levels of expression in squamous epithelia of mucosa, hematopoietic and immune cells. In normal kidney ANXA1 expression is mainly detected in glomeruli and in primary RCC.

ANXA was identified as a potentially interesting protein through systematic researches within The Human Protein Atlas ([www.proteinatlas.org](http://www.proteinatlas.org)) internal database for proteins. It was selected for further studies based on highly specific expression patterns in normal kidney and renal cancers on both immunohistochemistry level and RNA level [@B15]. In the present study we analyse the expression pattern of ANXA1 protein in a cohort of patients with advanced RCC to explore the potential role of ANXA1 as a predictive marker for sunitinib treatment. We also examine the predictive role of the combination of ANXA1 and membranous cubilin (CUBN) expression. We have recently demonstrated that CUBN is a prognostic and predictive factor in this patient group [@B19], [@B20].

Materials And Methods
=====================

Patients
--------

In an attempt to overcome some of the reporting deficiencies inherent in tumor marker studies we followed the REporting recommendations for tumor MARKer studies (REMARK) [@B21] when compiling this manuscript.

The Regional Ethical Committee (Uppsala, Sweden) granted approval for the study (2009/139) and patients still alive gave their written informed consent.

The cohort has been described previously [@B19] and consisted of 139 patients in seven Departments of Oncology in Sweden: Uppsala (n=48), Göteborg (n=36), Örebro (n=19), Västerås (n=12), Gävle (n=11), Falun (n=7) and Karlstad (n=6). These patients were diagnosed with mRCC between 2006 and 2010. All the patients had a prior nephrectomy and were thereafter treated with various therapeutic agents: TKI (sunitinib and sorafenib), mTOR inhibitor (temsirolimus), interferon α (IF-α) and/or bevacizumab. The patients (n=99) treated with sunitinib in the first or second line setting were selected for the current study. Twenty-two of these patients were excluded from analysis due to early side effects, which lead to the termination of treatment within 4 weeks, leaving 77 patients to the study.

Clinical data was collected, including the patient\'s age, gender and histologic subtype (Table [1](#T1){ref-type="table"}) as well as the length of treatment with sunitinib and sorafenib. Progression free survival was calculated as the time from the start of treatment to the time of clinical and/or radiological progression, treatment discontinuation due to toxicity or end of follow up. We also registered the OS calculated from the diagnosis of mRCC.

Tissue microarray (TMA) generation
----------------------------------

TMA, immunohistochemistry and slide scanning were essentially performed in accordance to standards used in the Human Protein Atlas ([www.proteinatlas.org](http://www.proteinatlas.org)) [@B15], [@B22]. In brief, corresponding HE slides were examined and representative tumor regions selected for the TMA. For each patient, two cores (1 mm in diameter) containing tumor tissue were collected (except in one case where there was only enough material for one core) by punch biopsy and transferred to recipient paraffin blocks subsequently containing 277 cores. TMArrayer™ (Pathology Devices, Westminster, MD, USA) and the Beecher Instruments Manual Tissue Arrayer MTA-1 (Estigen OÜ, Tartu, Estonia) were used for this procedure.

Immunohistochemical methods
---------------------------

Immunohistochemistry and slide scanning was performed at the Swedish Science for Life Laboratory (SciLifeLab) facilities in the Department of Immunology, Genetics, and Pathology at the Rudbeck Laboratory of Uppsala University. In brief, 4-μm TMA sections collected on SuperFrost Plus slides were prior to immunostaining deparaffinised in xylene, re-hydrated in graded alcohols, blocked for endogenous peroxidase, and subjected to heat-induced antigen retrieval. Automated IHC was performed using a LabVisionAutostainer 480S (Thermo Fisher Scientific, Runcorn, UK). Primary antibody towards Annexin A1 (HPA011272, Atlas Antibodies, Stockholm Sweden) was validated for immunohistochemistry according to criteria established by The Human Protein Atlas [@B22]. In Western blot, the ANXA1 antibody produced a single band corresponding to the predicted molecular weight, and showed great IHC consistency with four independent ANXA1 antibodies in a multitude of tissues, and IHC-data corresponded to the tissue-expression levels of ANXA as assessed by RNA-sequencing. All validation data can be found at <http://www.proteinatlas.org/ENSG00000135046-ANXA1/tissue>. The antibody was diluted 1:125 in UltraAb Diluent (Thermo Fisher Scientific, Fremont, CA, USA) and applied to the slides for 30 min at room temperature. The slides were further incubated with the secondary reagent, an anti-rabbitmouse horse reddish peroxidase-conjugated UltraVision (Thermo Fisher Scientific, Runcorn, UK) for 30 min at room temperature. Following the washing steps, the slides were developed for 10 min using the avidin-biotin peroxidase staining technique (Vector elite; Vector Laboratories, Burlingame, CA, USA), using 3.3-diaminobenzidine as the substrate. The slides were then counterstained with Mayer\'s haematoxylin for 5 min (Sigma-Aldrich, St.Louis, MO, USA) and coverslipped with Pertex (HistolabAB, Gothenburg, Sweden).

Slide scanning and evaluation of staining
-----------------------------------------

To obtain high-resolution digital images, the IHC slides were scanned with a 20x objective using the Aperio ScanScope XT Slide Scanner (Aperio Technologies, Vista, CA, USA).

The digital images were examined blindly in duplicates on a colour-calibrated screen using ImageScope (Aperio, Vista, CA, USA). Staining in the live tumor cells was semi-quantitatively evaluated by two observers, of which one pathology specialist (MN and AD) and disagreements were resolved by re-evaluation of the images. Three cellular compartments were annotated: nucleus, cytoplasm and membrane. Both staining intensity and the fraction of stained cells were categorically estimated using a scale of 0 to 3 for intensity (0=negative, 1=weak, 2=moderate, 3=strong), respectively of 0-4 for the fraction (0=0-1%, 1=2-25%, 2=26-50%, 3=51-75%, 4= 76-100%).

The distribution of the results for the cytoplasmic expression is given in Table [2](#T2){ref-type="table"}.

Representative examples of negative, weak, moderate and strong cytoplasmic intensity are shown in Figure [1](#F1){ref-type="fig"}.

Statistical methods
-------------------

For statistical analysis, the combined immune score for a cellular compartment was calculated by addition of the intensity score and fraction score, with a resulting scale from 0 to 7. For the cytoplasm staining the combined immune score 0-1 was defined as negative tumors and score 2-7 as positive tumors.

Statistical analyses (Kaplan-Meier method, log-rank test) were performed using STATISTICA program (version 2012). A two sided p-value \< 0.05 was defined as statistically significant.

Results
=======

Patients and follow-up
----------------------

Seventy patients were treated with sunitinib in the first and 29 in the second line setting. Sixteen of the 70 patients and six of the 29 patients were excluded from analysis because of early side effects, which lead to the termination of treatment. The 77 remaining patients were treated at median 7 months with sunitinib (range 0.5-34 months). Eleven patients were still on treatment at the end of the follow up time (Table [3](#T3){ref-type="table"}).

There were 53 males and 24 females in this final patient cohort. The median age of diagnoses in this group of patients was 62 years (range 40-76). Patients with localized disease at diagnosis (36 patients) were diagnosed with metastases 0-18 years later, median 2 years. Fourteen of these 36 patients developed metastatic disease during the first year after diagnoses. Forty-one patients had metastatic cancer already at diagnosis.

Median overall survival from the diagnoses of mRCC was 29 months (range 1-108 months). At the end of the study there were 16 patients still alive and 61 were deceased (Table [1](#T1){ref-type="table"}). The mean length of follow-up available for the surviving patients was 32 months (range 8-84).

ANXA1 expression
----------------

The primary end-point of the study was PFS (defined clinically and/or radiologically) and the second OS in regard with ANXA1 expression. For nuclei and membrane staining we found no correlations with the primary end point of the study (data not shown). For the cytoplasm staining, when using the cut-off value for combined staining score described above, 25/77 (32%) cases were ANXA1 negative.

The PFS was significantly better in patients with ANXA1 negative tumors (p = 0.02, Figure [2](#F2){ref-type="fig"}A). We observed that patients with ANXA1 positive tumors were treated with sunitinib in median 6.5 months (range 0.5-24 months) compared to ANXA1 negative patients with a median treatment time of 9 months (range 1-34 months). Patient age or gender showed no correlation to the cytoplasm expression of ANXA1 (data not shown).

Patients with negative ANXA1 staining had a significantly better OS (cytoplasm p = 0.0047, Figure [2](#F2){ref-type="fig"}B). The ANXA1 positive group had a median OS of 26 months (range 1-72 months) while ANXA1 negative had a median of 31 months (range 7-108 months).

The group in our TMA cohort of mRCC patients having received first or second line sorafenib treatment (n=53) was also analyzed. We found that cytoplasmic ANXA1 expression appears not to be associated with neither PFS, nor OS (p = 0.43/0.88 for cytoplasm) in these patients (Figure [3](#F3){ref-type="fig"}).

In an additional analysis, we combined expression of cytoplasmic ANXA1 and membranous CUBN. Patients with combination ANXA1 positive and CUBN negative tumor had significantly shorter PFS compared to the other combinations of expression as a group (p = 0.0017, Figure [4](#F4){ref-type="fig"}A) and compared to respective combination of expression. (p = 0.0038, Figure [4](#F4){ref-type="fig"}B).

Discussion
==========

There are several prognostic factors for RCC patients like number of metastatic sites, time from diagnosis to treatment, Karnofsky performance status, lactate dehydrogenase, hemoglobin, white blood count, platelets count, "corrected" serum calcium and alkaline phosphatase [@B23], [@B24]. However, no predictive marker exists. Sunitinib, an orally administered TKI, is one of the first and most used targeted therapies for these patients. ANXA1 is a protein that may inhibit inflammation while stimulating angiogenesis and exhibits differential expression in various tumors [@B11], [@B12]. In the present study we used a well-validated antibody to assess tumoral ANXA1 expression as a predictive marker for sunitinib treatment in mRCC patients.

VEGF- and PDGF-receptors are overexpressed in clear cell RCC due to inactivation of the tumor-suppressor gene von Hippel-Lindau (VHL) in the majority of the cases [@B25]. By inhibiting receptors of VEGF and PDGF, sunitinib prevents tumor angiogenesis, tumor growth and metastasis [@B26], [@B27]. A study of 750 mRCC patients showed that treatment with sunitinib compared to interferon-α prolonged PFS with six months (median) though it is important to note that some patients benefit much more while others have no gain at all from the treatment [@B3]. Considering this together with the fact that some patients experience severe side effects [@B28] and that the medication is costly stresses the need for a predictive marker.

It is well known that hypertension is a common side effect of TKIs. Further, hypertension related to sunitinib treatment in mRCC patients is associated with a better response and prolonged OS [@B7], [@B29]. Rini et al. studied over 500 mRCC patients treated with sunitib and found that PFS and OS were significantly longer for patients developing hypertension [@B30]. Thus, hypertension is considered an early evaluator of response to sunitinib treatment.

Most of the previous predictive marker studies in mRCC patients have focused on serum biomarkers for sunitinib treatment. Tumor necrosis factor α (TNF-α) and metalloproteinase-9 (MMP-9) baseline levels were measured in a small study of patients (n=21) treated with sunitinib [@B4]. Overexpression of both these proteins promote cancer development [@B31], [@B32]. Baseline levels were significantly increased in non-responders and significantly associated with a reduced time to progression (TTP) and OS. In a study of 85 patients treated with sunitinib high baseline levels of serum VEGF and neutropfilgelatinase-associated lipocalin (NGAL) indicated a higher relative risk of progression [@B5]. In a phase II study, patients with advanced urothelial cancer who were not suitable to receive standard treatment with cisplatin-based chemotherapy were treated with sunitinib in the first line setting (n=38). Interleukin 8 (IL-8) is a pro-inflammatory chemokine and a potent pro-angiogenic factor [@B33] and low pre-treatment levels were significantly associated with an increased TTP [@B34].

Serum is relatively easy to access to search for potential predictive factors but important features of the tumor might not be reflected systemically. In a TMA with substantially fewer mRCC patients than ours, potential predictive markers for response to sunitinib treatment were investigated. Hypoxia-inducible factor 1α (HIF-1α), CA9, CD31, VEGF receptors, pPDGFRα and -β and Ki67 were all associated with sunitinib response. In addition, a high HIF-1α expression was positively correlated to a longer PFS and a low PDGFRα score to a longer OS. Furthermore, patients with a low CA9 score a much shorter OS compared to patients with a high CA9 score [@B6]. In patients with advanced RCC receiving VEGF-targeted therapy (pazobanib or sunitinib), increased tumor cell PD-L1 or PD-L1 plus tumor CD8-positive T-cell counts predicted significantly shorter PFS and OS [@B35].

Several preclinical studies of ANXA1s function have been reported. In a mouse model of prostate cancer, cancer-associated fibroblasts (CAFs) secreted significantly higher levels of ANXA1 than normal prostate fibroblasts. ANXA1 secreted by CAFs induced prostate cancer cells to gain stem cells-like properties. This was accomplished through stimulation of differentiation and proliferation of the cancer stem-like cell population and through promoting generation of basal stem-like cells [@B36].

ANXA1 expression has also been shown to be associated with a highly invasive basal-like breast cancer subtype. Loss of ANXA1 expression reduced the number of lung metastases and high expression increased metastatic spread. ANXA1 stimulates metastatic development through stimulation of transforming growth factor β (TGF-β)/Smad signaling [@B37].

The neuroprotective effect of ANXA1 was explored and the findings indicate that ANXA1 promotes microglial activation and migration [@B38].

ANXA1 mimics the anti-inflammatory effects of glucocorticoids [@B11]. However, it has also been shown to be expressed on activated T- and B-cells, thereby promoting T-cell mediated immunity [@B39].

ANXA1 expression is associated with poor prognosis in cancer patients [@B16], [@B18]. The proposed pro-angiogenic activity of ANXA1 indicates that ANXA1 could be of predictive value for the anti-angiogenic drug sunitinib [@B12]. The current study is to our knowledge the first to investigate a potential predictive role for ANXA1.

In our study we found that patients with a low ANXA1 cytoplasmic expression in their primary tumors experienced a greater clinical benefit from sunitinib treatment in terms of a prolonged PFS. A possible explanation for this finding is that sunitinibs anti-angiogenic effect cannot overcome the pro-angiogenic drive from many ANXA1 proteins. We speculated that the sensitivity of the tumour to sunitinib therapy might be changed by the primary treatment and carried out a subgroup analysis. The difference in survival remained significant in the group having received sunitinib up front while no correlation was seen in the fewer mRCC patients who were treated with sunitinib after progression (data not shown). This subgroup analysis indicates that the value of ANXA1 as a predictive marker might be limited to the first line treatment setting.

In the group of patients in our cohort having received first or second line treatment with sorafenib, we found no association between ANXA1 expression and PFS or OS. The lack of significance might be explained by the limited number of patients, but since the survival curves show no tendency to separate, this is less likely. These findings indicate that ANXA1 expression is a specific predictive marker for sunitinib treatment, not for all TKIs.

In addition to PFS, the OS was also significantly longer in the ANXA1 (-) compared to the ANXA1 (+) sunitinib treated patients. A plausible explanation is that the gain in PFS is translated into a longer OS. However, some of the patients were later treated with other therapeutic agents, which could contribute to the difference in OS observed between the groups.

In the group of ANXA1 (+) cases, some patients benefitted from the treatment for many months. Hence, there is a need to better define the minor group of patients with no gain from sunitinib treatment. Therefore, we analyzed the combined expression of cytoplasmic ANXA1 and membranous CUBN. In our earlier study (19) we found that lack of membranous CUBN expression was a negative predictive marker for both sunitinib and sorafenib treatment. In the present study, the subset of patients with ANXA1 positive and CUBN negative tumor had significantly shorter PFS compared to other combinations of expression. This combined expression results in a higher predictive value than ANXA1 on its own and defines the population of patients who will not gain at all from sunitinib treatment.

We did not address the question how to detect patients who will experience severe side effects. Since the tumoral expression of ANXA1 is unlikely to reflect the reactions from the rest of the body, these patients were not included.

This study has some limitations. Due to its retrospective design, known serum prognostic markers (lactate dehydrogenase, hemoglobin, calcium) could for many patients not be recalled. Therefore, we were unable to assess whether ANXA1 has any prognostic value besides from being a predictive marker. Furthermore, the tumor response was not on a regular basis evaluated according to the Response Evaluation Criteria In Solid Tumors (RECIST) [@B40].

Conclusions
===========

In summary, we show for the first time that tumoral expression of ANXA1 is a potential predictive marker for sunitinib treatment in mRCC patients. ANXA1 expression in the cytoplasm was in our material associated with a significantly shorter PFS and OS. In addition, we found that the combination of positive cytoplasmic ANXA1 expression and negative membranous CUBN expression more accurately, than ANXA1 alone, defines the subset of patients who does not benefit from treatment. Our results need to be confirmed in further studies before ANXA1 and CUBN can be routinely used to select patients for sunitinib treatment.

We are grateful to all patients.
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![Representative images of the immunohistochemistry results for ANXA1 from primary renal cell carcinomas, from patients later treated for metastatic disease with sunitinib in the first or second line setting, demonstrating negative (A), weak (B), moderate (C) and strong (D) cytoplasmic staining in tumor cells.](jcav08p3975g001){#F1}

###### 

Progression free (A) and overall (B) survival for renal cancer patients treated for metastatic disease with sunitinib in the first or second line setting (n=77). ANXA1 (-) versus ANXA1 (+) tumors, cytoplasm.
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![Progression free survival for renal cancer patients treated for metastatic disease with sorafenib in the first or second line setting (n=53). ANXA1 (-) versus ANXA1 (+) tumors, cytoplasm.](jcav08p3975g004){#F3}

###### 

Progression free survival for renal cancer patients treated for metastatic disease with sunitinib in the first or second line setting (n=77). Cytoplasmic ANXA1 (+) and membranous CUBN (-) versus other combinations of expression as a group (A) and versus other combinations of expression respectively (B).
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###### 

Clinical characteristics of renal cancer patients treated for metastatic disease with sunitinib in the first- and second-line setting.

  Patient cohort                           Total n=77
  ---------------------------------------- --------------
  Gender, n (%)                            
  Male                                     53 (69)
  Female                                   24 (31)
  Age at diagnosis, years                  
  Median (range)                           62 (40-76)
  Age at metastatic disease, years         
  Median (range)                           64,5 (40-77)
  Histologictype, n (%)                    
  Clear cell                               68 (88)
  Papillary                                2 (3)
  Mixed phenotype                          2 (3)
  Unknown                                  5 (6)
  Local disease at diagnosis, n (%)        36 (47)
  Metastatic disease at diagnosis, n (%)   41 (53)
  Time to metastasis, years                
  Median (range)                           2 (0-18)
  Metastasis during first year, n (%)      14 (39)
  Metastasis after first year, n (%)       22 (61)
  Alive, n (%)                             16 (21)
  Dead, n (%)                              61 (79)
                                           

###### 

Distribution of cytoplasmic staining results among primary tumours of renal cancer patients treated for metastatic disease with sunitinib in the first- and second line setting (n=77).

  -------------------------------------------------------------------------------- ------------------------ --------------------- --------------------
  **Intensity of stained cytoplasm and distribution**                                                                             

  **Intensity**\                                                                   **Intensity**            **Cytoplasm**\        **Cytoplasm**\
  **Score**                                                                                                 **First Line**        **Second Line**

  0                                                                                Negative                 8                     0

  1                                                                                Weak                     27                    13

  2                                                                                Moderate                 14                    7

  3                                                                                Strong                   5                     3

  **Fraction of stained cytoplasm and distribution**                                                                              

  **Fraction**\                                                                    **Percentage Stained**   **Cytoplasm**\        **Cytoplasm**\
  **Score**                                                                                                 **First Line**        **Second Line**

  0                                                                                0-1%                     18                    8

  1                                                                                2-25%                    13                    5

  2                                                                                26-50%                   10                    3

  3                                                                                51-75%                   7                     3

  4                                                                                76-100%                  6                     4

  **Combined score (addition of intensity and fraction score) and distribution**                                                  

  **Combined**\                                                                    **Cytoplasm**\           **Cytoplasm**\        
  **Score**                                                                        **First Line**           **Second Line**       

  0                                                                                8                        0                     

  1                                                                                9                        8                     

  2                                                                                11                       3                     

  3                                                                                7                        2                     

  4                                                                                4                        1                     

  5                                                                                10                       7                     

  6                                                                                5                        1                     

  7                                                                                0                        1                     

  **Annexin A1 negative and positive cases**                                                                                      

  **ANXA1**\                                                                       **Cytoplasm**\           **Cytoplasm**\        **Cytoplasm**\
  **Expression**                                                                   **First Line (%)**       **Second Line (%)**   **Both Lines (%)**

  ANXA1 (-)                                                                        17 (31)                  8 (35)                25 (32)

  ANXA1 (+)                                                                        37 (69)                  15 (65)               52 (68)
  -------------------------------------------------------------------------------- ------------------------ --------------------- --------------------

###### 

Treatment characteristics for renal cancer patients treated for metastatic disease with sunitinib in the first- and second-line setting.

  Sunitinib treatment                                           Total n=99
  ------------------------------------------------------------- --------------
  Sunitinib first line, n (%)                                   70 (71)
  Sunitinib second line, n (%)                                  29 (29)
                                                                
  Side effects leading to discontinuation of treatment, n (%)   22 (22)
  first line                                                    16
  second line                                                   6
  Treated until progression/end of follow-up, n (%)             77 (78)
  first line                                                    54
  second line                                                   23
  Median PFS, months (range)                                    7 (0,5-34)
  first line                                                    7,8 (0,5-34)
  second line                                                   6 (1-24)
  Still under treatment, n (%)                                  11 (14)
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